NSABP C-14

NSABP C-14

CORRECT- MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease.

Protocol Chair: Mohamed Salem, MD

Protocol Officer: Shannon Puhalla, MD

Patient Population:
colorectal

Target Accrual: 750 patients

Status: Active, Not Recruiting

ClinicialTrials.gov Identifier: TBD